|
Published by: Datamonitor
Published: Sep. 24, 2002 - 161 Pages
Table of Contents
Overview
Introduction
Hepatitis B &C are both relatively immature treatment markets. Companies wishing to enter these markets will face strong competition from established key players. The analysis within this report provides an overview of key HBV and HCV pipeline products as well as analysis of the current hepatitis market, in order to provide a strategic guide to successful market penetration. In addition, revenue forecasts to 2010 are included, utilizing Datamonitor's new interactive forecasting tool.
Scope
Overview of the patient potential of HCV and HBV across the seven major markets, as well as HBV epidemiology in the emerging markets
Specific breakdown of the HCV population by symptoms, genotype and ethnic origin, and the implications this will have on the future treatment market
Report Highlights
A key unmet need in the treatment market continues to be low response rates in patients suffering from HCV genotype 1, despite improvements in interferon treatment. The focus of the HCV market will therefore shift towards antiviral combination therapy by 2015 to combat growing physician dissatisfaction.
Reasons to Purchase
Optimize your knowledge of company and product strategies in the HBV and HCV markets.
Identify key products in the R&D pipeline.
Target research and development resources more effectively through an understanding of unmet needs and key clinical trial data.
Scope
Overview of drugs in late and early stages of development, plus analysis of major companies involved in the R&D pipeline
Recommendations of key R&D strategies including case studies of companies utilizing these strategies
Comprehensive analysis of late-stage roducts, with Datamonitor forecasts of drug revenues to 2010
DRIVERS AND TRENDS
Both the Hepatitis B (HBV) and Hepatitis C (HCV) markets are increasing in size and as such are becoming more and more attractive to the pharma industry. A deeper understanding of the viral infections is enhancing drug development, whilst an increase in treatment options is driving market growth. Both the HBV and HCV markets are set to become more competitive over the next ten years, and company strategy will determine the success of new products.
TREATMENT OVERVIEW
What is the patient potential within the HCV and HBV markets? This section provides an overview of HCV and HBV epidemiology in the seven major markets of the US, Japan, France, Germany, Italy, Spain and the UK, enabling you to assess the patient potential of HBV and HCV. HCV genotype distribution is reviewed, and epidemiology of HBV in the emerging markets of SE Asia, and vaccine coverage in these regions is also given.
MARKET OVERVIEW
What is the current value of the hepatitis market, and what are the products currently available to treat HBV and HCV? This section outlines global unmet needs of the hepatitis market, and provides a breakdown in 2001 treatment sales of HBV and HCV products, alongside a breakdown of the HBV prophylaxis market.
The strengths, weaknesses, opportunities and threats of current drugs on the hepatitis market are also analyzed.
PIPELINE ANALYSIS
How does the immediate future in hepatitis treatment look? The Pipeline Analysis section reviews products that are currently in development for HBV and HCV, providing analysis of the marketing strengths, weaknesses, opportunities and threats of key products in late stage development.
THE FUTURE DECODED
Which drugs will dominate the market over the next eight years? This chapter provides hepatitis market sales forecasts for up to 2010 for both current products and key products in late stage development. It summarizes the factors that Datamonitor believes will be the key impacts on the future market.
ANALYST INSIGHT
What are the optimal strategies to adopt when entering the hepatitis markets?
This section provides a strategic insight into the hepatitis market, giving an overview of strategies to be considered when competing in the hepatitis market and illustrating specific points with actual case studies.
DATASETS
Table 1: Prevalence of Different HCV Genotypes in the Seven Major Markets (%)
Table 2: Sustained Viral Response (SVR) of Genotypes to Different Treatment Regimens
Table 3: Total Hepatitis Sales, 2001, by Company
Table 4: Breakdown of the Total Hepatitis Market Sales Forecast ($)
Table 5: The Diagnosed HCV Patient Population in the Seven Major Markets, 2001
Table 6: Prevalence of Different HCV Genotypes in the Seven Major Markets (%)
Table 7: Sustained Viral Response (SVR) of Genotypes to Different Treatment Regimens
Table 8: Breakdown of US HCV Population by Race
Table 9: Chronic HBV Prevalence and Vaccine Coverage in the Emerging Markets, 2001
Table 10: Breakdown of the HCV Treatment Market, 2001
Table 11: Breakdown of the HBV Treatment and Vaccine Market, 2001
Table 12: Total Hepatitis Sales, 2001 by Company
Table 13: Global Zeffix Sales 2000 and 2001
Table 14: Total Global Hepatitis Vaccine Sales for GSK, 2000-2001
Table 15: HCV Products in Phase II and III Clinical Trials
Table 16: HCV Products in Phase I Clinical Trials
Table 17: HCV Drugs in Research and Pre-Clinical Development
Table 18: HBV Products in Phase III Clinical Trials
Table 19: HBV Products in Phase II Clinical Trials
Table 20: HBV Products in Phase I and Development Stages
Table 21: Breakdown of the Total Hepatitis Market Sales Forecast ($)
Table 22: Major Factors Impacting the Interferon Market 2001-2010
Table 23: Major Factors Impacting the Antiviral Market 2001-2010
AbstractIntroduction: Hepatitis B and C are both relatively immature treatment markets. Companies wishing to enter these markets will face strong competition from established key players. The analysis within this report provides an overview of key HBV and HCV pipeline products as well as analysis of the current hepatitis market, in order to provide a strategic guide to successful market penetration. Scope of the Report: * Overview of the patient potential of HCV and HBV across the seven major markets, as well as HBV epidemiology in the emerging markets * Specific breakdown of the HCV population by symptoms, genotype and ethnic origin, and the implications this will have on the future treatment market * Overview of drugs in late and early stages of development, plus analysis of major companies involved in the R&D pipeline * Recommendations of key R&D strategies including case studies of companies utilizing these strategies * Comprehensive analysis of late-stage products, with Datamonitor forecasts of drug revenues to 2010 Datamonitor's new forecasting methodology. Report Highlights: A key unmet need in the treatment market continues to be low response rates in patients suffering from HCV genotype 1, despite improvements in interferon treatment. The focus of the HCV market will therefore shift towards antiviral combination therapy by 2015 to combat growing physician dissatisfaction. Key Reasons to buy this Report: * Optimize your knowledge of company and product strategies in the HBV and HCV markets. * Identify key products in the R&D pipeline. * Target research and development resources more effectively through an understanding of unmet needs and key clinical trial data.
Get Full Details About This Report >>
|
